Reducing Varicella Severity
COULD MEAN THE WORLD TO THEM
VARIZIG® reduces the severity and complications of varicella disease in high-risk individuals1
About VARIZIG
VARIZIG is the only varicella zoster Immunoglobulin for post-exposure prophylaxis.
Varicella zoster virus (VZV) infection remains a significant concern for high-risk populations. VARIZIG is proven to reduce disease severity and complications and is recommended by leading guidelines as first the line for VZV post-exposure prophylaxis. 1,2,3,4
Risk Groups for Severe Varicella Zoster Disease and Complications 1
Immunocompromised Patients without Immunity to Varicella
Pregnant Women without Immunity to Varicella
Infants without Immunity to Varicella
Reasons to Trust VARIZIG
VARIZIG is the Standard of Care for Post Exposure Prophylaxis of Varicella Zoster Virus According to the Leading Guidelines3
Established Efficacy in Reducing Disease Severity and Complications5
Established Safety in High-Risk Patients5
Learn more about VARIZIG Safety & Efficacy
Learn more about
VARIZIG® Safety & Efficacy
About KAMADA
WE ARE KAMADA. WE BELIEVE THAT EACH LIFE IS UNIQUE.
Established more than three decades ago, Kamada is a global biopharmaceutical company focused on innovative specialty hyperimmune globulin therapies to save and improve the lives of patients with limited treatment alternatives.
Kamada’s primary focus is on solid organ transplant and individuals at high risk of contracting infectious diseases.
We are invested in innovative science and foster strong partnerships with the community to improve the lives of patients.
We have a broad hyperimmune portfolio, with 6 FDA-approved immunoglobulin (IgG) products and the unique ability to rapidly develop new hyperimmune plasma IgG therapies.
References: [1] VARIZIG® [package insert]. Kamada Inc September 2022. [2] Varicella-Zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, 2019. [3] The CDC updated Recommendations for Use of VARIZIG®-United States, 2013. [4] Red-Book: 2024-2027 Report of the Committee on Infectious Diseases. 4. Centers for Disease Control and Prevention (CDC): Guidelines on the prevention of VZV infections, including post-exposure prophylaxis. [5] Levin MJ, Duchon JM, Swamy GK, Gershon AA (2019): Varicella-zoster immune globulin (VARIZIG®) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded access program. PLoS ONE 14(7): e0217749.